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Available online 24 July 2019Background: Thymidine kinase 2 (TK2) catalyses the phosphorylation of deoxythymidine (dThd) and
deoxycytidine (dCtd)withinmitochondria. TK2 deficiency leads tomtDNAdepletion or accumulation ofmultiple
deletions. In patients, TK2mutations typically manifest as a rapidly progressive myopathy with infantile onset,
leading to respiratory insufficiency and encephalopathy in the most severe clinical presentations. TK2-
deficient mice develop the most severe form of the disease and die at average postnatal day 16. dThd+dCtd ad-
ministration delayed disease progression and expanded lifespan of a knockin murine model of the disease.
Methods:We daily administered TK2 knockout mice (Tk2KO) from postnatal day 4 with equimolar doses of dThd
+dCtd, dTMP+dCMP, dThd alone or dCtd alone. We monitored body weight and survival and studied different
variables at 12 or 29 days of age. We determined metabolite levels in plasma and target tissues, mtDNA copy
number in tissues, and the expression and activities of enzymeswith a relevant role inmitochondrial dNTP anab-
olism or catabolism.
Findings: dThd+dCtd treatment extended average lifespan of Tk2KO mice from 16 to 34 days, attenuated growth
retardation, and rescuedmtDNA depletion in skeletal muscle and other target tissues of 12-day-oldmice, except
in brain. However, the treatmentwas ineffective in 29-day-oldmice that still died prematurely. Bioavailability of
dThd and dCtdmarkedly decreased duringmouse development. Activity of enzymes catabolizing dThd and dCtd
increased with age in small intestine. Conversely, the activity of the anabolic enzymes decreased in target tissues
duringmouse development.We also found that administration of dThd alone had the same impact on survival to
that of dThd+dCtd, whereas dCtd alone had no influence on lifespan.
Interpretation: dThd+dCtd treatment recruits alternative cytosolic salvage pathways for dNTP synthesis, suggest-
ing that this therapy would be of benefit for any Tk2mutation. dThd accounts for the therapeutic effect of the
combined treatment inmice. During thefirstweeks after birth,mice experiencemarked tissue-specificmetabolic
regulations and ontogenetic changes in dNTPmetabolism-related enzymes that limit therapeutic efficacy to early
developmental stages.
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. This is an open access article under1. IntroductionThymidine kinase 2 (TK2), a mitochondrial enzyme encoded by nu-
clear DNA, catalyses a limiting step in mitochondrial deoxynucleoside
(dN) salvage. This pathway recycles dNs from endogenous metabolism
and diet by using a set of kinases that catalyse equivalent reactions in
the cytosol and mitochondria. TK2 phosphorylates the pyrimidine dNs,
deoxythymidine (dThd) and deoxycytidine (dCtd), to deoxythymidine
monophosphate (dTMP) and deoxycytidine monophosphate (dCMP),
respectively. These deoxynucleoside monophosphates (dNMPs) are
consecutively phosphorylated to deoxynucleoside triphosphatesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Thymidine kinase 2 (TK2) is a key enzyme formitochondrial pyrim-
idine dNTP synthesis.Mutations in TK2 reduce availability of dTTP
and dCTP and interfere with normal mitochondrial DNA (mtDNA)
replication leading typically to a severe and rapidly-progressive
myopathy. Supplementation with precursors in the form of
deoxynucleosides (dNs), specifically deoxythymidine (dThd) and
deoxycytidine (dCtd), activates the synthesis of dTTP and dCTP
through alternative enzyme pathways and effectively counteracts
the defect in a knockin mouse model of the disease.
These results prompted the compassionate use of dThd plus dCtd
for the treatment of patients suffering TK2 deficiency with signifi-
cant positive results so far.
Added value of this study
Here, we use an alternative mouse model completely devoid of
TK2 activity (knockout mouse) with a fatal encephalomyopathy
phenotype, similar to that observed for the knockin mice. We con-
firm that administration of dThd+dCtd, delays disease progres-
sion, doubles life expectancy and counteracts mtDNA depletion
inmost target tissues of young knockout mice. In addition, we ob-
serve how administration of dThd alone leads to the same thera-
peutic effect in terms of survival. However, important tissue-
specific metabolic regulations predict different outcomes for the
combined or individual therapy depending on the target tissue.
Both TK2-deficient mouse models die prematurely in spite of the
treatment. In this study, we deeply characterize metabolic re-
sponse to dNs-treatment, and identify decreased activity of sal-
vage kinases and increased deoxynucleoside catabolism as key
factors limiting therapeutic efficacy to early developmental stages
in mice.
Implications of all the available evidence
No effective therapeutic optionwas available for TK2 deficient pa-
tients before dTMP and dCMPwere proposed, followed by the ob-
servation that the active compounds in this treatment are dThd
and dCtd. In themost severe cases, TK2-deficient patients die dur-
ing early infancy. After recent experience of compassionate use of
dThd and dCtd in TK2 deficiency, a cohort of patients is being
treated with positive effects on survival, motor and respiratory
function. Hence, it is at the utmost importance to understand
how dThd and dCtd exert their metabolic effect and what factors
may be lessening their therapeutic potential.
Our study will be crucial for the design of a next-coming clinical
trial for TK2-deficiency treatment and will surely be of interest in
expanding dN-based therapies for the treatment of other mito-
chondrial DNA depletion syndromes.
Fig. 1. Schematic representation of themain enzyme pathways involved inmitochondrial
pyrimidine dNTPs metabolism. Proteins involved in the de novo synthesis pathway are
depicted in blue. Kinases involved in the deoxynucleoside salvage pathway are depicted
in red. Enzymes participating in catabolism of dNs are depicted in purple. Nucleoside
transporters from cytosol to mitochondria are represented in green. Abbreviations: CDA,
cytidine deaminase; cdN, cytosolic deoxyribonucleotidase; dCTD, dCMP deaminase; dCK,
deoxycytidine kinase; ENT1, equilibrative nucleoside transporter 1; mdN, mitochondrial
deoxyribonucleotidase; NDPK, nucleotide diphosphate kinase; NMPK, nucleotide
monophosphate kinase; TK1, thymidine kinase 1; TK2, thymidine kinase 2; TP,
thymidine phosphorylase; TS, thymidylate synthase; RNR, ribonucleotide reductase.
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lication [32] (Fig. 1). Thus, mutations in TK2 result in mitochondrial
deoxythymidine triphosphate (dTTP) and deoxycytidine triphosphate
(dCTP) insufficiency, dNTP pool imbalance, and consequent mtDNA de-
pletion or accumulation of multiple mtDNA deletions [2,11,26,29].
The clinical presentation of TK2 deficiency is mainly myopathic.
Based on the age at onset and severity, patients can be classified into
three main groups, from the most severe and common to the milder
and less frequent manifestations: 1) infantile-onset myopathy with oc-
casional neurological involvement, severe mtDNA depletion, and early
death; 2) childhood-onset myopathy with mtDNA depletion and mod-
erate to severe progression of weakness; and 3) late-onset myopathywith mild limb weakness and slow progression to respiratory insuffi-
ciency [11].
Two different TK2-deficient mouse models have been generated to
investigate the molecular mechanism of this disease, a knockin model
for a common pathogenic mutation, p.His121Asn in humans (p.
His126Asn inmice) [1], and a knockout mouse [34]. In patients, TK2 de-
ficiency predominantly causesmyopathy, but bothmousemodels man-
ifest major central nervous system (CNS) involvement, with
development of fatal encephalomyopathy resembling the most severe
cases of the disease in humans [11,12].
Therapies designed to feed dN salvage have proven to delay disease
progression and increase survival. The first pre-clinical studies on the
knockin model intended to bypass the TK2 defect with administration
of dTMP and dCMP. This treatment augmentedmtDNA levels in the tar-
get tissues and prolonged survival with dose-related efficacy, although
phenotype rescue was incomplete and mice still died prematurely be-
fore adulthood [10]. Based on these results, dNMPs were first used to
treat a few patients [6]. Later studies identified dNs as the active agents
following dNMPs administration. dNMPs are charged compounds and
in the absence of a known transporter, they cannot be internalized by
cells. In addition, dNMPs are rapidly dephosphorylated to dNs in vivo
by nucleotidases and phosphatases [4,35]. In a later study using the
same mouse model, López et al. found that co-administration of dThd
and dCtd yielded similar results [16]. These positive data served as a
proof-of-concept that dNs could be effective therapeutic agents for
TK2 deficiency, and prompted their use as compassionate therapy. So
far, the treatment has provided clinically significant benefits, especially
in infantile- and childhood-onset cases, and has led to improvement or
stabilization of respiratory function in late-onset cases after a few years
or even months of therapy [6].
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prematurely [16]. As there is no currently available alternative therapy
for patients with TK2 deficiency, it is crucial to determine what ele-
ments may act to lessen the efficacy of dNs. Here, using the knockout
model generated by Zhou et al. [34], we perform a deep analysis of the
mechanisms regulating dNTP homeostasis and identify factors that
should be key for leveraging the therapeutic potential of dNs.
2. Materials and methods
2.1. Ethics statement
This study was conducted in accordance with the rules established
by the Generalitat de Catalunya for the Care and Use of Laboratory Ani-
mals. The protocol was approved by the Ethics Committee for Animal
Experimentation of the Vall d'Hebron Research Institute (Permit Num-
ber: 02/17).
2.2. Mice housing, treatment administration, tissue collection and
endpoints
The studywas carried out with TK2 knockoutmice (Tk2KO) (C57BL/6
genetic background) previously generated and characterized as de-
scribed [34]. Mice were housed and bred in a standard controlled envi-
ronment under a 12-h light-dark cycle with ad libitum access to water
and regular rodent chow diet. Tk2KO mice develop a fatal encephalomy-
opathy and die at around twoweeks of age.Wemonitored bodyweight,
general behaviour and appearance, and survival on a daily basis. For eth-
ical reasons, we euthanizedmice in the survival studieswhen theywere
too weak to move in the cage and thereby obtain necessary food and
drink.
Treatment was administered daily by single-dose oral gavage
starting from postnatal day 4. Solutions of dThd, dCtd, dTMP, and
dCMP were prepared in PBS, filter-sterilized, and stored at 4 °C (−20
°C for long-term storage) until administered to Tk2KO mice and wild-
type littermates (Tk2WT). dThd and dCtd were administered, either
combined or individually, each at a dose of 400 mg/kg/day (165 mM
dThd and 176 mM dCtd), whereas dTMP and dCMP were co-
administered at an equimolar dose of 620mg/kg/day. A group of control
mice was administered PBS solution (vehicle).
Mice were sacrificed at 12 or 29 days of age (except those included
in the survival analysis) 1 h after treatment administration (coinciding
with maximum bioavailability of the administered treatments in
blood, as assessed in our preliminary pharmacokinetic studies). The
health status of treated Tk2KO mice degenerated gradually, showing
the first signs of weakness a few days before death. Hence, to prevent
dehydration and malnutrition at early stages of the disease, we pro-
vided all litters with accessible semi-solid food from day 15.
Circulating peripheral blood (mice at 12 days of age) or cardiac
puncture blood (mice at 29 days of age) was collected in EDTA
(Microvette capillary tubes, SARSTEDT) and processed (3500 g at 4 °C
for 5min) to obtain plasma. Sampleswere stored at−20 °C until further
use. Tissues (brain, liver, and skeletalmuscle [gastrocnemius])were col-
lected, immediately frozen in liquid nitrogen and stored at−80 °C until
further use. The small intestine lumen was cleansed with abundant sa-
line solution prior to freezing in liquid nitrogen.
2.3. mtDNA copy number determination
Total DNAwas isolated from frozen tissues ground in liquid nitrogen
(QIAamp DNA Mini Kit, Qiagen) and dissolved in 10 mM Tris-HCl
(pH 8). For each sample, 1:3 dilutions and duplicates were assessed.
Quantitative real-time PCR reactionswere performed in 384-well plates
using the TaqMan Universal PCR Master Mix II, with UNG (Applied
Biosystems). Custom-designed sets of TaqMan primers and probes
were used for relative mtDNA (16S rRNA gene [30]) versus nDNA(angiogenin 1 [Ang1, Mm00833184_s1] single copy gene) copy number
quantification. Two different standard curves with cloned 16S rRNA and
Ang1 amplicons were used for absolute quantification of mtDNA
and nDNA. Detection was done using an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems).
2.4. Determination of metabolite levels in mouse plasma and tissues
dThd, dCtd, and their degradation products (thymine [Thy] and
deoxyuridine [dUrd], respectively) weremeasured in plasma and tissue
samples by liquid chromatography coupled to tandem mass spectrom-
etry (LC-MS/MS), using an LC-MS/MS system (Acquity UPLC-XevoTM
TQ Mass Spectrometer, Waters, Milford, MA, USA). Frozen tissues
were ground in liquid nitrogen and homogenized in lysis buffer
(50mMTris-HCl, pH 7.2; 1% Triton X-100; 2 mM phenylmethylsulfonyl
fluoride; 0.02% 2-mercaptoethanol; 100 μM tetrahydrouridine (THU);
and 100 μM 6-amino-5-bromouracile [6A5BrU]) by mechanical disrup-
tion using a plastic pestle. Deuterated dThd (1 μM; Cambridge Isotope
Laboratories)was used as an internal standard. Homogenateswere cen-
trifuged at 20,000g at 4 °C for 30 min, and supernatants were collected.
Protein concentration was measured by the Bradford method. Diluted
plasma and tissue homogenates were deproteinised by ultrafiltration
(10 kDa Amicon Ultra filters, Millipore) at 14,000 g at 4 °C for 30 min
and stored at 20 °C until further use. Samples and standards were
loaded into 96-well plates for injection in the LC-MS/MS system. For
all determinations, the stationary phase was an Acquity UPLC BEH C18
column (100× 2.1mm, 130 Å pore, 1.7mmparticle,Waters). For deter-
minations, 7.5 μl of sample was injected into the LC-MS/MS system and
resolved at 0.5 ml/min through a binary gradient elution using a saline
buffer (20 mM ammonium acetate, pH 5.6) and acetonitrile as follows:
time 0–1.1 min, isocratic 100% saline buffer; 1.1–5 min, gradient from 0
to 13.6% acetonitrile; 5–5.1min, gradient from13.6 to 100% acetonitrile;
5.1–6.1 min, isocratic 100% acetonitrile; and 6.1–7.2 min, isocratic 100%
saline buffer. Detection of the eluate components was performed using
multiple reaction monitoring, in positive electrospray mode with the
following m/z transitions: 255.0 N 133.8 (deuterated dThd), 242.8
N 127.1 (dThd), 228.8 N 113.1 (dUrd), 227.9 N 112.1 (dCtd), and 126.7
N 110.0 (Thy). Identification of all compounds was based on the reten-
tion time and specific ion transitions. Calibration curves made with
aqueous multistandards were processed in parallel, and concentrations
were obtained from interpolation of the peak areas using TargetLynx
software (Waters).
2.5. RNA isolation and analysis of expression
RNAwas isolated from frozen tissues ground in liquid nitrogen with
TRIzol Reagent (Invitrogen), resuspended in RNAase-free water, and
quantified using a NanoDrop spectrophotometer. A 5-μg amount of
RNA was treated with DNaseI (Ambion DNAse-free) and reverse tran-
scribed to cDNA by using the High-Capacity cDNA Archive Kit (Applied
Biosystems). Quantitative real-time PCR reactions were carried out in
384-well plates with TaqMan Universal PCR Master Mix II, with
UNG (Applied Biosystems). Predesigned TaqMan Gene Expression
Assays (AppliedBiosystems)wereused for detectionof thymidinephos-
phorylase (Tymp; Mm01301808_m1), cytidine deaminase (Cda,
Mm01341706_m1), thymidine kinase 1 (Tk1, Mm01246403_g1) and
deoxycytidine kinase (Dck, Mm00432794_m1) mRNA. Each sample
was analysed in triplicate, and the average value was used as the
mRNAmeasure. mRNA levels of cyclophilin A (Ppia;Mm02342430_g1)
were used as the reference for normalization among samples.
2.6. Enzyme activity determinations
Catabolic activities thymidine phosphorylase (TP) and cytidine de-
aminase (CDA) were adapted from Martí et al. [19]. Briefly, frozen tis-
sues were ground in liquid nitrogen and homogenized in lysis buffer
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fluoride [PMSF]; 0.02% 2-mercaptoethanol) by mechanical disruption
with a plastic pestle. Homogenates were centrifuged at 20,000g at 4 °C
for 30 min, and supernatants collected for protein concentration deter-
mination by the Bradford method. A 100-μg amount of protein was in-
cubated at 37 °C for 1 h with 10 mM dThd in a total volume of 100 μl
reaction buffer (0.1 M Tris-arsenate, pH 6.5) for TP activity or with
5 mM dCtd in a total volume of 100 μl reaction buffer (0.2 M Tris-HCl,
pH 8; 100 μM 6-amino-5-bromouracile [6A5BrU]) for CDA activity. A
blank in which dThd or dCtd was omitted, was also processed for each
sample. The reaction was stopped by addition of 1 ml of 0.55 M HCl to
all samples and 10mMdThd or dCtd to all blanks. Samples were centri-
fuged at 20,000g at 4 °C for 10 min. Supernatants were injected into an
Acquity UPLC system (Waters, Milford, MA, USA), and eluted at
0.5 ml·min-1 with a saline buffer eluent (20 mM ammonium acetate,
pH 5.6) and an organic eluent (methanol gradient grade), according to
the following gradient: time 0–1.1 min, isocratic 100% saline buffer;
1.1–5 min, gradient from 0 to 13.6% methanol; 5–5.1 min, gradient
from 13.6 to 100% methanol; 5.1–6.1 min, isocratic 100% methanol;
and 6.1–7.2 min, isocratic 100% saline buffer. The column used was an
Acquity UPLC BEH C18 column (100 × 2.1 mm, 130 Å pore size, 1.7
μm particle size [Waters]). Eluate absorbance was monitored at
267 nm, and the Thy (product of TP reaction) or dUrd (product of CDA
reaction) peaks were identified and quantified using a multistandard
calibration curve.
Anabolic activities thymidine kinase 1 (TK1) and deoxycytidine ki-
nase (dCK) were measured using a radiochemical method [24]. Briefly,
tissue homogenates were prepared as for TP and CDA determinations
in lysis buffer (50 mM Tris-HCl, pH 7.2; 1% Triton X-100; 2 mM PMSF;
0.02% 2-mercaptoethanol). Homogenates were centrifuged at 20,000g
for 30 min at 4 °C, and supernatants collected for protein concentration
determination by the Bradfordmethod. A 120-μg amount of extract was
incubated for 1 h at 37 °C in a reaction buffer (50 mM Tris-HCl, pH 7.6;
5 mMMgCl2; 5 mMATP; 10 mMNaF; 2 mM DTT; 0.5 mg/ml BSA) con-
taining appropriate [3H]-labelled substrates (Moravek, Inc.) and inhibi-
tors. For TK1 activity, 25 μM [methyl-3H]-Thd, 1 mM (for brain
determinations) or 100 mM (for liver determinations) dCtd, 100 μM
THU, and 100 μM 6A5BrU were used. For dCK activity, 25 μM [3H]-
dCtd, 10 mM dThd, 100 μM THU, and 100 μM 6A5BrU were used. THU
and 6A5BrU were added to prevent degradation of the substrates. As
TK2 can phosphorylate both substrates and interfere with specific de-
termination of TK1 and dCK activity, we used an excess of competitive
substrates (dCtd or dThd respectively) to inhibit TK2-dependent phos-
phorylation in the two reactions. In preliminary assays, we determined
the inhibitory capacity of competitive substrates of each enzyme and
calculated the final values accordingly. After incubation, the reactions
were spotted on DEAE Filtermat filters (Perkin Elmer) and left to air-
dry. Filters were washed twice for 5 min in 1 mM ammonium formate,
and for 5 additional min in water, and then left to air-dry. Dried filters
were coated with MeltiLex scintillation wax (Perkin Elmer). The reac-
tion product retained in the filters was detected and quantified with a
MicroBeta2 system (Perkin Elmer). Results are expressed in pmols of
the product (dTMP or dCMP) formed permg of protein permin. Activity
measurementswere done in triplicate and quantified using a calibration
curve.
2.7. Statistical analysis
Statistical analysis was performed with GraphPad Prism 6 software.
The specific tests used for each assay are indicated in the Results section
or the figure legends. For statistical purposes, undetectable values were
considered zero.Mice sacrificed for plasmaand tissue collection, ormice
that died due to experimental manipulation were considered as cen-
sored observations in Kaplan-Meier statistical analyses. Detailed infor-
mation on animals included in the survival study is provided in
Supplementary Table 1.2.8. Data availability
The datasets generated during the experimental procedures and
analysis are available from the corresponding author on reasonable
request.
3. Results
3.1. Daily administration of pyrimidine deoxynucleosides extends life ex-
pectancy of a mouse model devoid of TK2 enzyme activity
We treated TK2 knockout (Tk2KO) pups and wild-type littermates
(Tk2WT) with dThd plus dCtd (each at 400 mg/kg/day), an equimolar
dose of the corresponding dNMPs, dTMP plus dCMP (each at 620
mg/kg/day), or phosphate buffered saline (PBS, vehicle) by daily oral ga-
vage starting at postnatal day 4. Previous studies have shown that un-
treated TK2KO mice die prematurely at around two weeks of age [34].
We obtained similar results after daily oral PBS administration. PBS-
treated Tk2KO mice exhibited pronounced weight loss starting at 14 to
15 days of age and died shortly after (median, 16 days of age; mean
±SD, 16.3±2.6 days of age; n=20) (Fig. 2). Treatmentwith either py-
rimidine dNMPs (dTMP+dCMP) or the corresponding dNs (dThd
+dCtd) delayed disease progression and strongly attenuated growth
retardation (Fig. 2). Survival of Tk2KO mice treated with dThd+dCtd or
dTMP+dCMP was extended up to 34 or 32 (median) days of age
(mean ± SD, 31.9 ± 6.9 days of age; n = 12; mean ± SD, 34.1 ±
6.0 days of age; n= 11, respectively) (Fig. 2A). There were no adverse
effects in Tk2WT littermates treated up to 41 days with either PBS or
dThd+dCtd (up to 51 days with dTMP+dCMP).
These results are equivalent to those obtained with an alternative
TK2-deficient model, the p.His126Asn knockin mouse, exposed to sim-
ilar treatments [1,10,16].
3.2. dThd+dCtd administration rescues mtDNA copy number in skeletal
muscle only at early ages
We analysed Tk2KO mice and Tk2WT littermates at two time-points,
at 12 days of age, close to the stage when untreated or PBS-treated
Tk2KO naturally die [34], and 29 days of age, close to the maximum
survival achieved with treatment. At day 12, Tk2KO mice showed a sig-
nificantly reduced mtDNA copy number in skeletal muscle (gastrocne-
mius), and particularly, in brain (Fig. 3). Treatment with dThd+dCtd
rescued mtDNA depletion only in skeletal muscle. On day 29, we were
only able to study Tk2WT and treated Tk2KO animals because PBS-
treated Tk2KO mice do not survive beyond 20 days of age. At this stage,
mtDNA depletion was obvious in all analysed tissues of treated Tk2KO
animals (liver, brain, and skeletal muscle) with the exception of small
intestine, indicating that the treatment had failed to rescue mtDNA
copy number in any case.
Furthermore, dThd+dCtd treatment elevated mtDNA copy number
in several tissues of Tk2WT mice. This increase was significant at
12 days of age in liver and at 29 days in skeletal muscle (Fig. 3).
3.3. dThd and dCtd bioavailability markedly decreases during mouse
development
We collected blood and tissues 1 h after dThd+dCtd administration
and determined concentrations of the two dNs and their first catabolic
products, thymine (Thy) and deoxyuridine (dUrd), respectively. As
was expected, plasma concentrations of both dNs were significantly
higher after treatment, with dCtd reaching half the levels of dThd
(Fig. 4). Nevertheless, administration of the same doses of dThd+dCtd
resulted in much lower plasma levels of these compounds in 29-day-
old mice (mean ± SD of dThd: Tk2WT-dThd+dCtd 40.6 ± 17.0; Tk2KO-
dThd+dCtd 25.4 ± 9.0; mean ± SD of dCtd: Tk2WT-dThd+dCtd 7.5
± 9.8; Tk2KO-dThd+dCtd 2.9 ± 1.7) than in the 12-day-old littermates
Fig. 2. Co-administration of dThd+ dCtd increases life expectancy and attenuates disease progression in Tk2KO mice. Tk2KO mice (solid lines) and Tk2WT (dashed lines) littermates were
daily administered PBS (vehicle; 10 μl/g), 400 mg/kg of dThd+dCtd, or an equimolar dose of 620 mg/kg of dTMP+dCMP. (A) Survival proportions, Kaplan-Meier curve (Tk2WT-PBS, n=
47; Tk2KO-PBS, n=58; Tk2WT-dThd+dCtd, n=55; Tk2KO-dThd+dCtd, n=48; Tk2WT-dTMP+dCMP, n=14; Tk2KO-dTMP+dCMP, n=11.Mantel-Cox test: Tk2KO-PBS versus Tk2WT-PBS,
p b .001; Tk2KO-dThd+dCtd versus Tk2KO-PBS, p b .001; Tk2KO-dTMP+dCMP versus Tk2KO-PBS, p b .001; Tk2KO-dTMP+dCMP versus Tk2KO-dThd+dCtd, non-significant differences).
Censored observations appear as black ticks in the graph (B) Weight progression for female and male mice (Males: Tk2WT-PBS, n = 30; Tk2KO-PBS, n = 32; Tk2WT-dThd+dCtd, n =
40; Tk2KO-dThd+dCtd, n = 36; Tk2WT-dTMP+dCMP, n = 7; Tk2KO-dTMP+dCMP, n = 3. Females: Tk2WT-PBS, n = 30; Tk2KO-PBS, n = 25; Tk2WT-dThd+dCtd, n = 35; Tk2KO-dThd
+dCtd, n = 32; Tk2WT-dTMP+dCMP, n = 7; Tk2KO-dTMP+dCMP, n= 8. Results represent mean values for each time point; error bars indicate SD).
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+dCtd 190.2 ± 54.5; mean ± SD of dCtd: Tk2WT-dThd+dCtd 90.9 ±
11.2; Tk2KO-dThd+dCtd 82.6 ± 27.1) (Fig. 3). Likewise, although the
age-related differences were not as marked, we observed the same
trend for Thy and dUrd plasma levels (Fig. 4).
We also determined dThd, dCtd, Thy, and dUrd levels in the 4 differ-
ent tissues (brain, liver, skeletal muscle, and small intestine). Given the
presence of dNs-dedicated transporters in cell membranes [33], we ex-
pected that the intracellular levels would largely mirror the concentra-
tion of these compounds in plasma. In fact, dThd+dCtd administration
triggered an increase in the levels of all compounds in all tissues of
12-day-old mice analysed at only 1 h after oral administration (Fig. 5
and Supplementary Fig. 1). Again, levels of the therapeutic dNs and
those of their first catabolic products were significantly lower in tissues
from older animals. dThd and dCtd concentrations were particularlyhigh in small intestine, likely due to active absorption of these com-
pounds after oral administration (Fig. 5).
In general, we found no marked genotype-related differences, ex-
cept for a trend in which dThd and dUrd concentrations were slightly
lower in treated Tk2KO mice than in Tk2WT (dThd from 29d Tk2WT-
dThd+dCtd vs Tk2KO-dThd+dCtd: plasma p b .05, brain and liver p b
.01; dUrd from 29d Tk2WT-dThd+dCtd vs Tk2KO-dThd+dCtd: plasma
and brain p b .05, liver p b .01. P-values obtained with the Mann-
Whitney U test) (Figs. 4 and 5, and Supplementary Fig. 1).
3.4. Expression and activity of key metabolic enzymes undergo marked on-
togenetic changes
In the absence of TK2 activity, phosphorylation of administered
dThd and dCtd necessarily depends on the catalytic activity of
Fig. 3. Co-administration of dThd+ dCtd rescues mtDNA depletion in targeted tissues of Tk2KOmice only at an early age. mtDNA and nDNA levels were determined by quantitative real-
time PCR inmice aged 12 (12d) or 29 days (29d). Results indicate the ratio ofmtDNA to nDNA in brain, liver, skeletal muscle (gastrocnemius), and small intestine of Tk2KO (KO; triangles)
and Tk2WT (WT; dots)mice, treatedwith either 400mg/kg/day of dThd+dCtd (+; blue) or PBS (−; green). Tissueswere collected 1 h after oral gavage. Scatter plots represent themedian
(horizontal line) with interquartile range (mice for each group in brain, n = 7–18; liver, n = 7–18; skeletal muscle, n = 7–18 and small intestine, n = 5–8). P-values obtained with the
Mann-Whitney U test: *p b .05; **p b .01; ***p b .001; ns, non-significant differences. Age-related statistical significance lines and p-values are in red.
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deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1), catalyse
equivalent reactions to TK2 outside mitochondria. We investigated ex-
pression of these key anabolic enzymes in tissues of PBS-treated or
dThd+dCtd-treated Tk2WT and Tk2KO littermates at 12 and 29 days of
age.
Downregulation of TK1 expression has already been described
during normal mouse development [7]. Accordingly, we found de-
creased Tk1 mRNA expression in all analysed tissues from 29-day-
old mice relative to that of 12-day-old mice (except for small intestine
where Tk1 mRNA levels remained unchanged in both age groups)
(Fig. 6A). Interestingly, we found that Tk1 mRNA levels were
sustained specifically in brain of treated 29-day-old Tk2KO mice. Be-
cause we lacked a working antibody that specifically recognized
mouse TK1 protein, we were unable to determine TK1 protein levels.
We also found that 12-day-old Tk2KO-PBS mice had slightly increased
(in liver) and decreased (in skeletal muscle) Tk1 mRNA levels. How-
ever, these changes were not confirmed when TK1 enzyme activity
was tested in liver and brain (Fig. 6B). In liver, TK1 activity was re-
duced in older animals, whereas in brain, it was particularly low al-
ready at 12 days of age.
DckmRNA expression had decreased in liver of all 29-day-old mice
regardless of their genotype, although the decrease was greater in
treated Tk2KO mice (Fig. 6A). Enzyme activity (Fig. 6B) determinations
in brain and liver correlated with steady state dCK protein levels
assessed by western blot (Supplementary Figs. 2 and 3) and confirmed
a considerable dCK reduction in both tissues during normal mouse de-
velopment. Interestingly, this decreased was not observed in brain
from Tk2KO mice.An important factor that regulates the bioavailability of adminis-
tered dNs is the activity of catabolic enzymes responsible for their deg-
radation. Thymidine phosphorylase (TP) is the main enzyme catalysing
degradation of dThd in humans andmice (although in the latter, dThd is
also substrate for uridine phosphorylase [8]). Cytidine deaminase (CDA)
is the enzyme catalysing dCtd deamination, thefirst step in the catabolic
pathway of this dN [9]. We performed a preliminary longitudinal study
of TP and CDA activities in untreated wild-type mice up to 70 days of
age. Up to 30 days of age, we observed no major differences over time
in brain and skeletal muscle (very low activity for both enzymes), but
therewas a clear increase in the activity of both enzymes in small intes-
tine and a decrease in liver (Supplementary Fig. 4). Hence, we decided
to focus on liver and small intestine for a deeper study in all treated an-
imal groups.
We confirmed that TympmRNA expression (Fig. 7A) and TP activity
(Fig. 7B), weremarkedly higher in small intestine of oldermice. This ob-
servation is in agreement with the high Thy concentration found in in-
testine of 29-day-old mice (Fig. 5). CDA activity was higher than TP
activity at early stages of development, but in small intestine it also in-
creased with age. Upregulation of both TP and CDA enzyme activity
and mRNA levels in small intestine suggests this tissue may be impor-
tant for limiting the efficacy of orally administered dThd and dCtd.
In liver, we also observed an upregulation of Tymp mRNA levels
(Fig. 7A) and TP activity (Fig. 7B) at 29 days of age, specifically in treated
Tk2KO animals. Conversely, CdamRNA expression (Fig. 7A) and activity
(Fig. 7B) were downregulated in liver from older mice. Some genotype-
related changes in CdamRNA expressionwere also revealedwith either
increases (in brain) or decreases (in skeletal muscle), specifically in 29-
day-old treated Tk2KO mice (Fig. 7A). Nonetheless, as untreated or PBS-
Fig. 4. Bioavailability of administered dThd+dCtd descreaseswith age. Concentrations of dThd, dCtd and their first degradation products (dUrd and Thy) in plasma ofmice aged 12 (12d)
or 29 days (29d) by LC-MS/MS. Results indicatemetabolite concentrations (μM) in plasma of Tk2KO (KO; triangles) and Tk2WT (WT; dots)mice, treatedwith either 400mg/kg/day of dThd
+dCtd (+; blue) or PBS (−; green). Blood was collected 1 h after oral gavage. Scatter plots represent the median (horizontal line) with interquartile range (12d: Tk2WT-PBS, n= 13;
Tk2WT-dThd+dCtd, n = 13; Tk2KO-PBS, n = 17; Tk2KO-dThd+dCtd, n = 6. 29d: Tk2WT-PBS, n = 10; Tk2WT-dThd+dCtd, n = 11; Tk2KO-dThd+dCtd, n = 6). P-values obtained with
the Mann-Whitney U test: ***p b .001; ns, non-significant differences. Age-related statistical significance lines and p-values are in red.
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a contribution of chronic daily dThd+dCtd administration to these
observations.
3.5. dThd alone is responsible for the therapeutic effect
Even though the two dNs were administered at the same dose, we
systematically observed lower bioavailability for dCtd than for dThd
(Figs. 4 and 5). This observation prompted us to investigate the contri-
bution of each dN to the therapeutic effect. To this end, we administered
dThd or dCtd to independent groups of Tk2KO and Tk2WT littermates. Ad-
ministration of 400 mg/kg/day dCtd had no effect on the lifespan of
Tk2KO (median, 15 days of age; mean ± SD, 17.7 ± 1.5 days of age; n
=6), but administration of the same dose of dThd increased life expec-
tancy to a median of 33 days (mean ± SD, 34.2 ± 2.6 days of age; n=
12), similar to the values obtained after combined administration of
dThd+dCtd at the same dose (Fig. 8A). In addition, the body weight
evolution in dThd-treated Tk2KO was equivalent to that observed with
the combined treatment (Fig. 8B).
In light of these results, we proceeded to investigate bioavailability
and mtDNA copy number in a group of animals given only dThd (400
mg/kg/day). We found that plasma dThd concentration was around
two-fold higher in these animals than in those administered dThd
+dCtd at the same dose (Figs. 4 and 9). A mild increase in dUrd plasma
concentration occurred in parallel to the increased bioavailability of
dThd (Fig. 9), likely because of substrate competition between dThdand dUrd for TP activity. We observed a similar relative increase
for dThd and Thy concentration in brain and skeletal muscle of
dThd-treated mice. However, in small intestine and liver, either
dThd or Thy concentrations were equivalent in some groups
to those achieved after combined administration of dThd+dCtd
(Supplementary Fig. 5). In contrast, acute oral administration of the
same dose of dCtd alone resulted in concentrations similar to those
found in animals receiving the combined therapy (Supplementary
Fig. 6).
Analysis of mtDNA copy number in brain, liver and small intestine
evidenced a better response after administration of dThd alone than
when combined with dCtd (Fig. 9B and Fig. 3). In general, all groups of
mice experienced a greater increase in mtDNA copy number after
dThd administration, including Tk2WT mice (Fig. 9B).
Importantly, mtDNA copy number nearly normalized in brain of 12-
day-old Tk2KO animals treated with dThd only, whereas the combined
treatment induced no positive response in this tissue. However, in skel-
etal muscle of mice at the same age, a better response was achieved
after combined dThd+dCtd administration (Fig. 9B). These findings
suggest that complex tissue-specific metabolic regulations may affect
the outcome of dN-based therapies.
At a later stage, 29-days of age, liver, brain and especially skeletal
muscle, experience a marked increase in mtDNA copy number as part
of their normal development (as indicated by the increase observed in
Tk2WT mice). At this timepoint, no treatment was able to normalize
mtDNA levels.
Fig. 5. dThd and dCtd concentrations in tissues are lower in older mice. dThd and dCtd concentrations in brain, liver, skeletal muscle (gastrocnemius), and small intestine determined by
LC-MS/MS. Results are expressed in nmols per mg of protein in tissues of mice aged 12 (12d) or 29 days (29d). Tk2KO (KO; triangles) and Tk2WT (WT; dots) mice, treated with either 400
mg/kg/day of dThd+dCtd (+; blue) or PBS (−; green). Tissues were collected 1 h after oral gavage. Scatter plots represent the median (horizontal line) with interquartile range. Mice in
each group, n= 5. P-values obtained with the Mann-Whitney U test: *p b .05; **p b .01; ns, non-significant differences.
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Previous studies had shown that dN supplementation delays disease
progression and expands survival in a knockin mouse model for the p.
His121Asn mutation [10,16]. However, kinetic studies revealed that
the mutant protein retains its capacity for dThd phosphorylation, sug-
gesting that increased substrate concentration might stimulate residual
enzyme activity [31]. The fact that dThd+dCtd administration has a
similar effect on a knockout model devoid of any TK2 enzyme activity[34] aswas shownhere, leads to the conclusion that dNsmust recruit al-
ternative pathways for their ultimate transformation into dNTPs. This
would imply that this type of therapymay be effective for any TK2 path-
ogenic mutation whether or not there is any residual enzyme activity.
Although we observed a notable effect on survival, which doubled
with dThd+dCtd treatment, Tk2KO mice still exhibited growth retarda-
tion and prematurely died before adulthood (median survival,
34 days). Thus, the therapy delays disease progression but fails to
completely rescue the phenotype in mice. In an attempt to uncover
Fig. 6. dN anabolic enzyme mRNA expression and activity decrease during mouse development. We measured mRNA levels and enzyme activity of cytosolic salvage kinases involved in
dThd and dCtd activation (TK1 and dCK, respectively) in various targeted tissues from mice aged 12 (12d) or 29 days (29d). Tissues were collected 1 h after oral gavage. Scatter plots
represent the median (horizontal line) with interquartile range. P-values obtained with the Mann-Whitney U test: *p b .05; **p b .01; ns, non-significant differences. (A) Relative Tk1
and Dck mRNA levels in brain, liver, skeletal muscle (gastrocnemius), and small intestine, determined by real-time PCR with specific TaqMan probes. PpiamRNA level was used for
normalization between samples. Results are represented as the fold change related to the mean value in 12-day-old PBS-treated Tk2WT mice. Mice in each group, n= 5. (B) TK1 and
dCK enzyme activities in brain and liver, determined using a biochemical method with specific radiolabelled substrates. Results are represented as pmol of product formed in 1 min
from 1 mg of protein in tissue homogenate. Mice in each group, n= 6. Age-related statistical significance lines and p-values are in red.
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tifiedontogenetic changes in the expressionof related catabolic enzymes
and necessary cytosolic salvage kinases. dThd and dCtd bioavailability
was clearly reduced in older mice. The activity of CDA and principally
TP, which catalyse the first degradation step of dCtd and dThd, respec-
tively,wasmarkedly increased in small intestine of oldermice, a decisive
tissue for the bioavailability of orally administered substances. Accord-
ingly, in tissues of older mice, the decrease in dThd and dCtd levels was
generally larger than that of their respective catabolic products, in agree-
ment with higher degradation activities. Other routes of administration,
such as intraperitoneal (IP) injection leads to higher bioavailability of
dThd+dCtd. However, IP administration of dThd+dCtd to a TK2His126Asn knockin mouse model yielded similar results on survival
[17], so reduced efficacy of deoxynucleosides with aging is likely due to
factors other than simply absorption at the level of small intestine. The
activity of the required cytosolic deoxynucleoside kinases (TK1 and
dCK) was also markedly altered with age, especially in brain and liver
where both activities were significantly reduced, which could also con-
tribute to the age-related loss of effect. Overall, our findings regarding
these limiting factors are in agreement with the observations on a TK2
His126Asn knockin mice after IP and oral dThd+dCtd administration
[16,17]. Finally, ontogenetic changes in other factors, such as dN trans-
porters involved in intestinal absorption and cellular internalization,
could further lessen the therapeutic potential of dNs in older mice.
Fig. 7. dNs catabolic enzyme mRNA expression and activity is upregulated in small intestine of older mice. mRNA levels and enzyme activity of the main catabolic enzymes involved in
dThd and dCtd degradation (TP and CDA, respectively) in various target tissues of mice aged 12 (12d) or 29 days (29d). Tissues were collected 1 h after oral gavage. Scatter plots
represent the median (horizontal line) with interquartile range. P-values obtained with the Mann-Whitney U test: *p b .05; **p b .01; ns, non-significant differences. (A) Relative Tymp
and CdamRNA levels of in brain, liver, skeletal muscle (gastrocnemius), and small intestine determined by real-time PCRwith specific TaqMan probes. PpiamRNA level was used for nor-
malization between samples. Results are represented as the fold change relative to the mean value in 12-day-old PBS-treated Tk2WTmice. Mice in each group, n=5. (B) TP and CDA en-
zyme activities, determinedby a biochemicalmethod coupled toUPLC analysis in liver and small intestine. Results are represented as nmol of product formed in 1 h from1mgof protein in
tissue homogenate. Mice in each group, n = 5. Age-related statistical significance lines and p-values are in red.
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ready at early ages. As an example, while mtDNA was repopulated in
skeletal muscle of young treated Tk2KO mice in response to combined
administration of dThd and dCtd, the same treatment triggered no de-
tectable increase in mtDNA copy number in brain, another targeted tis-
sue. dNs can cross the blood-brain barrier through the activity of
dedicated transporters [23,28]. Accordingly, our results showed a
marked increase in brain dN concentrations already 1 h after adminis-
tration, suggesting that lack of effectiveness depends on downstream
events, such as the extremely low TK1 activity detected in this tissue
which makes it more dependent on TK2 activity [7,27].
Interestingly, although TK2 is responsible for both dThd and dCtd
phosphorylation in mitochondria, we found that the therapeutic effectof the combined therapy on survival in mice actually depends on dThd
alone. Non-dividing cells are highly dependent on deoxynucleoside sal-
vage due to downregulation of de novo dNTP synthesis pathways
(Fig. 1). Unlike dCK, which is ubiquitously expressed throughout cell
cycle, TK1 expression is highly linked to S-phase during cell cycle
[13,22]. Thus, mtDNA synthesis demands for dCTP are possibly lower
than for dTTP in the absence of functional TK2 activity. In fact, adminis-
tration only of dThd led to a higher mtDNA repopulation index in most
tissues of 12-day-old mice, including brain, in which levels were much
closer to normalization than after dThd plus dCtd co-administration.
This effect is consistent with the finding of higher plasma and tissue
dThd concentration after administration of dThd alone, which is likely
due to interactions of both these pyrimidine dNs with transporters
Fig. 8. dThd is responsible for extended survival and slowed disease progression. in Tk2KOmice. Tk2KOmice (solid lines) and Tk2WT (dashed lines) littermateswere daily administered PBS
(vehicle; 10 μl/g; green lines), 400mg/kg of dThd+dCtd (blue lines), 400 mg/kg of dCtd (orange lines) or 400mg/kg of dThd (red lines). PBS and dThd+dCtd treatedmicewere included
also in Fig. 1. (A) Survival proportions, Kaplan-Meier curve (Tk2WT-dThd, n= 10; Tk2KO-dThd, n= 12; Tk2WT-dCtd, n= 9; Tk2KO-dCtd, n = 6. Mantel-Cox test: Tk2KO-PBS versus Tk2KO-
dThd p b .001; Tk2KO-dThd versus Tk2KO-dThd+dCtd no significant differences; Tk2KO-dThd+dCtd versus Tk2KO-dCtd p b .001; Tk2KO-PBS versus Tk2KO-dCtd; ns, non-significant
differences). Censored observations appear as black ticks in the graph (B) Growth progression for female and male mice (Males: Tk2WT-dThd, n = 9; Tk2KO-dThd, n = 12; Tk2WT-dCtd,
n = 8; Tk2KO-dCtd, n = 3. Females: Tk2WT-dThd, n = 10; Tk2KO-dThd, n = 5; Tk2WT-dCtd, n = 3; Tk2KO-dCtd, n = 4. Results represent mean values for each time point; error bars
indicate SD).
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sponse in brain provides evidence that the extremely low TK1 levels
in this tissue can still be stimulated by high concentrations of substrate,
(ie, dThd), a particularly relevant finding from the standpoint of thera-
peutic effectiveness, and is another indication that reduced availability
of dNs with age may be an important limitation to this therapy.
In contrast to what occurs in humans, whomainly manifest TK2 de-
ficiency as a purely myopathic condition [11,25], mice show marked
CNS involvement [1,3,34]. Thus, the ability of dThd to repopulate
mtDNA in brain appeared to be a key factor defining the effectiveness
of this treatment in mice. Nevertheless, survival after dThd administra-
tion alone was equivalent to survival after the combined therapy. Up-
regulation of catabolic enzymes, and particularly of TP, at a later age
leads to lower dThd concentrations in plasma and lowermtDNA repop-
ulation in all target tissues, which possibly leads to ultimately equiva-
lent effects on survival than after the combined therapy of dThd+dCtd.Taken together, our results would seem to argue against any need
for dCtd, as it apparently provided no benefits over dThd alone in
mice. However, the dCtd increase after treatment was smaller than
that of dThd already at early stages of development. Thus, we cannot
rule out the possibility that a positive response might be triggered in
Tk2KO mice by increasing dCtd availability. Furthermore, although
higher dThd availability led to better results in brain, it had a detrimen-
tal effect on mtDNA copy number in skeletal muscle of young Tk2KO
mice, indicating that demands for the different dNTP species may vary
between the various target tissues. A similar observation has been
made by López-Gómez et al. in liver from older TK2-deficient mice
[17]. Such tissue-specific metabolic requirements and homeostasis
make it difficult to define the contribution of each particular tissue to
the therapeutic intervention and to the overall disease phenotype. In
addition, othermousemodels for dNTPmetabolism-related defects dis-
play phenotypes that are remarkably different from those in humans
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tween the two species. All these observations prevent us from anticipat-
ingwhether dCtd administrationmay be dispensable in humans, where
muscle is actually the main tissue affected.
Other issues should also be considered when analysing factors with
a potential impact on therapy efficacy. It is possible that a lack of TK2 ac-
tivity could trigger some adaptive changes that would be detected as
genotype-linked differences. Nonetheless, we detected scarce differ-
ences between genotypes at day 12 of age, and on day 29, the observa-
tions were challenged by the absence of PBS-treated Tk2KO mice, which
did not survive beyond day 20. Also, animals were exposed to daily
treatment starting from postnatal day 4. Thus, we cannot exclude that
our observations in Tk2KO mice on day 29 may be due to the combined
effect of chronic exposure to treatment and genotype adaptations. For
example, we observed higher Dck and Cda mRNA levels in brain of
Tk2KO. Liver TP activity, and consequently Thy levels, were also higher,
specifically in Tk2KO mice. In agreement with this observation, we
found that concentrations of dThd and dUrd, both substrates of TP,
were lower in various tissues of treated Tk2KO (Figs. 4 and 5 and Supple-
mentary Fig. 1).
Garone et al. reported an increase in TK1 activity after chronic dTMP
and dCMP administration [10]. We found that Tk1mRNA levels, which
normally drop with age, were sustained in brain from treated Tk2KO
mice (Fig. 6A). This interesting result suggests that the high dThd levels
could stabilise TK1 by increasing TK1 transcription. In fact, although TK1
undergoes specific proteolysis in mitotic exit, dThd binding to TK1 has
been shown to stabilise the enzyme during growth arrest in HeLa cells
[14]. However, our activity measurements did not corroborate our
mRNA observations, which suggest a participation of posttranslational
degradation mechanisms that would counteract upregulation of TK1
transcription [13]. Furthermore, it is important to note that 29-day-old
Tk2KO mice are at a late stage of the disease, so some of the effects ob-
served may be associated with this circumstance.
TK2 deficiency reduces dTTP and dCTP levels, interfering with
mtDNA replication. By activating alternative salvage pathways, the
treatment provided enough substrates to counteract mtDNA depletion
inmost tissues from young Tk2KOmice. In addition, increased dThd con-
centration also led to increased mtDNA levels in treated Tk2WT mice. In
Tk2WT, expansion of the mitochondrial dTTP pool counts on functional
TK2 activity in addition to cytosolic salvage. In fact, the increase in
mtDNA levels was higher in some tissues of Tk2WT than of Tk2KO mice
(Fig. 9). These results suggest that basal dNTP levels, actually limit
mtDNA replication in normal physiological conditions, at least in some
tissues.
Unbalanced dNTP pools may have detrimental consequences for
DNA replication fidelity [20]. Mutation frequencies in nuclear andmito-
chondrial genome seemednot affected in transgenic Tk2KOmice overex-
pressing cytosolic DmdNK, which lead to a 200-fold and 5-fold
expansion of dTTP and dCTP pools respectively [15]. Nevertheless, mu-
tagenesis and other dN therapy-related safety issues will necessarily be
addressed in further research.
Despite the significant differences between humans and mice re-
garding dNTP homeostasis, we believe the results of this study provide
insight into the pathomechanisms underlying TK2 deficiency and offer
useful information on key factors that could limit the efficacy of dNs-
based therapies. These data are of value, as dNs are currently beingFig. 9.Higher dThd concentration correlateswith highermtDNA copy number in targeted tissue
12 (12d) or 29 days (29d) and of Tk2KO (KO; triangles) or Tk2WT (WT; dots)mice, treatedwith e
and bloodwere collected 1 h after oral gavage. Scatter plots represent themedian (horizontal lin
b .01; ***p b .001; ns, non-significant differences. (A) Concentration (μM) of dThd, Thy, dCtd and
23; Tk2WT-dThd, n= 8; Tk2KO-PBS, n=17; Tk2KO-dThd+dCtd, n=14; Tk2KO-dThd, n= 5. 29d
n = 8; Tk2KO-dThd, n = 9). (B) mtDNA and nDNA levels were determined by quantitative re
(gastrocnemius), and small intestine (mice in each group in brain, n = 5–10; liver, n = 5–10;applied in clinical use in TK2-deficient patients [6], and they will be of
interest in the design of an upcoming clinical trial.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
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